BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

Orna emerged from stealth Wednesday with an $80 million A round to develop circular RNA therapies for cancer and genetic diseases that could be easier to manufacture than linear RNAs and immune cell therapies. MPM Capital,...
BioCentury | Feb 27, 2021
Product Development

How variant surveillance could drive a sequencing boom

The push to keep up with COVID-19 variants could be the inflection point that turns genomic sequencing from a sophisticated technique into a widely accessible tool, with companies in the driver...
BioCentury | Feb 27, 2021
Product Development

FDA to authorize J&J COVID-19 vaccine Saturday, CDC recommendation Sunday

With a unanimous endorsement by an FDA advisory committee and the agency poised to issue an emergency authorization Saturday, the next inflection point for the Johnson & Johnson COVID-19 vaccine will...
BioCentury | Feb 27, 2021
Product Development

Feb. 26 COVID Quick Takes: FDA wants more data from Merck; plus ‘clear efficacy’ for Regeneron and updates from GSK, Lilly, Novavax

Merck & Co. Inc. (NYSE:MRK) no longer expects to supply the U.S. with COVID-19 therapy MK-7110 by June 30 after FDA told the company additional data would be needed to support emergency use authorization. MK-7110,...
BioCentury | Feb 27, 2021
Deals

Feb. 26 Quick Takes: Venrock leads Artiva’s crossover-laden $120M series B; plus Roivant-Silicon, Origin, Sino-Akeso, Tricida, LISCure

NK cell therapy company Artiva Biotherapeutics Inc. raised $120 million in a series B financing led by Venrock Healthcare Capital Partners. Other new investors participating included Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton,...
BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

University of California Berkeley and University of California San Francisco announced Thursday a research collaboration with Genentech Inc. to develop therapies for CNS disorders. The universities will receive up to $53 million over 10 years from...
BioCentury | Feb 26, 2021
Emerging Company Profile

Immune-Onc building broad pipeline of myeloid checkpoint inhibitors

Launched in 2016, Immune-Onc is part of a growing class of immuno-oncology companies converting myeloid cells from immune-suppressing into tumor-suppressing agents. The Palo Alto-based company was co-founded by serial entrepreneur Guo-Liang Yu, an OrbiMed Advisors...
BioCentury | Feb 26, 2021
Distillery Therapeutics

Zelboraf-based PROTAC for melanoma, lung cancer expressing BRAF mutations

DISEASE CATEGORY: Cancer INDICATION: Melanoma; lung cancer A Yale University and Memorial Sloan Kettering Cancer Center team led by Arvinas Inc. (NASDAQ:ARVN) founder Craig Crews created a PROTAC based on Zelboraf vemurafenib that could treat BRAF...
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...
BioCentury | Feb 26, 2021
Product Development

Zaks’ impending departure but the latest milestone as Moderna charts year ahead

As Moderna prioritizes maximizing the reach of its COVID-19 vaccine, Thursday’s announcement of the impending departure of longtime CMO Tal Zaks caps a transformational 14 months for the mRNA company and comes during a year when...
Items per page:
1 - 10 of 44715
BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

Orna emerged from stealth Wednesday with an $80 million A round to develop circular RNA therapies for cancer and genetic diseases that could be easier to manufacture than linear RNAs and immune cell therapies. MPM Capital,...
BioCentury | Feb 27, 2021
Product Development

How variant surveillance could drive a sequencing boom

The push to keep up with COVID-19 variants could be the inflection point that turns genomic sequencing from a sophisticated technique into a widely accessible tool, with companies in the driver...
BioCentury | Feb 27, 2021
Product Development

FDA to authorize J&J COVID-19 vaccine Saturday, CDC recommendation Sunday

With a unanimous endorsement by an FDA advisory committee and the agency poised to issue an emergency authorization Saturday, the next inflection point for the Johnson & Johnson COVID-19 vaccine will...
BioCentury | Feb 27, 2021
Product Development

Feb. 26 COVID Quick Takes: FDA wants more data from Merck; plus ‘clear efficacy’ for Regeneron and updates from GSK, Lilly, Novavax

Merck & Co. Inc. (NYSE:MRK) no longer expects to supply the U.S. with COVID-19 therapy MK-7110 by June 30 after FDA told the company additional data would be needed to support emergency use authorization. MK-7110,...
BioCentury | Feb 27, 2021
Deals

Feb. 26 Quick Takes: Venrock leads Artiva’s crossover-laden $120M series B; plus Roivant-Silicon, Origin, Sino-Akeso, Tricida, LISCure

NK cell therapy company Artiva Biotherapeutics Inc. raised $120 million in a series B financing led by Venrock Healthcare Capital Partners. Other new investors participating included Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton,...
BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

University of California Berkeley and University of California San Francisco announced Thursday a research collaboration with Genentech Inc. to develop therapies for CNS disorders. The universities will receive up to $53 million over 10 years from...
BioCentury | Feb 26, 2021
Emerging Company Profile

Immune-Onc building broad pipeline of myeloid checkpoint inhibitors

Launched in 2016, Immune-Onc is part of a growing class of immuno-oncology companies converting myeloid cells from immune-suppressing into tumor-suppressing agents. The Palo Alto-based company was co-founded by serial entrepreneur Guo-Liang Yu, an OrbiMed Advisors...
BioCentury | Feb 26, 2021
Distillery Therapeutics

Zelboraf-based PROTAC for melanoma, lung cancer expressing BRAF mutations

DISEASE CATEGORY: Cancer INDICATION: Melanoma; lung cancer A Yale University and Memorial Sloan Kettering Cancer Center team led by Arvinas Inc. (NASDAQ:ARVN) founder Craig Crews created a PROTAC based on Zelboraf vemurafenib that could treat BRAF...
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...
BioCentury | Feb 26, 2021
Product Development

Zaks’ impending departure but the latest milestone as Moderna charts year ahead

As Moderna prioritizes maximizing the reach of its COVID-19 vaccine, Thursday’s announcement of the impending departure of longtime CMO Tal Zaks caps a transformational 14 months for the mRNA company and comes during a year when...
Items per page:
1 - 10 of 44715